585 results found
Tawakol A, Singh P, Rudd JHF, et al., 2014, Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A(2) Inhibitor, on Arterial Inflammation as Assessed With F-18-Fluorodeoxyglucose-Positron Emission Tomography Imaging, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 63, Pages: 86-88, ISSN: 0735-1097
Matthews PM, Edison P, Geraghty OC, et al., 2014, The emerging agenda of stratified medicine in neurology, NATURE REVIEWS NEUROLOGY, Vol: 10, Pages: 15-26, ISSN: 1759-4758
Harvey NC, Matthews P, Collins R, et al., 2013, Osteoporosis epidemiology in UK Biobank: a unique opportunity for international researchers, OSTEOPOROSIS INTERNATIONAL, Vol: 24, Pages: 2903-2905, ISSN: 0937-941X
Zarei M, Beckmann CF, Binnewijzend MAA, et al., 2013, Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease (vol 66, pg 28, 2013), NEUROIMAGE, Vol: 83, Pages: 1109-1109, ISSN: 1053-8119
Colasanti A, Owen DR, Grozeva D, et al., 2013, Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18 kDa Translocator Protein (TSPO), PSYCHONEUROENDOCRINOLOGY, Vol: 38, Pages: 2826-2829, ISSN: 0306-4530
Wu C, Zhu J, Baeslack J, et al., 2013, Longitudinal Positron Emission Tomography Imaging for Monitoring Myelin Repair in the Spinal Cord, ANNALS OF NEUROLOGY, Vol: 74, Pages: 688-698, ISSN: 0364-5134
Colasanti A, Guo Q, Mulhert N, et al., 2013, [18F]PBR111 binding in lesional and peri-lesional multiple sclerosis white matter, 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Publisher: SAGE PUBLICATIONS LTD, Pages: 68-69, ISSN: 1352-4585
Guo Q, Colasanti A, Owen DR, et al., 2013, Quantification of the Specific Translocator Protein Signal of18F-PBR111 in Healthy Humans: A Genetic PolymorphismEffect on In Vivo Binding, Journal of Nuclear Medicine, Vol: 54, Pages: 1-9
PET is used to image active inflammatory processes by targetingthe translocator protein (TSPO). In vitro, second-generation TSPOradioligands, such as PBR111, have been shown to bind to humantissue samples with either high affinity (high-affinity binders, HABs),low affinity (low-affinity binders, LABs), or an intermediate, mixedaffinity (mixed-affinity binders, MABs). We previously explainedthese differences in affinity in human tissue via the rs6971 polymorphismin the TSPO gene and predicted that the specific signalfrom PET ligands in vivo would vary accordingly. In silico modelingpredicted that 18F-PBR111 would have a moderate to high specificto-nonspecific ratio in the normal human brain. To test these predictions,we present here the analysis and modeling of 18F-PBR111data in healthy humans. Methods: Twenty-one subjects (9 HABs, 8MABs, and 4 LABs), 28–62 y old, genotyped for the rs6971 polymorphism,underwent 120-min PET scans with arterial samplingafter a bolus injection of 18F-PBR111. Compartmental models andLogan graphical methods enabled estimation of the total volume ofdistribution (VT) in regions of interest (ROIs). To evaluate the specificsignal, we developed 2 methods to estimate the nondisplaceablevolume of distribution (VND): the first assumed that the in vitro affinityratio of 18F-PBR111 in HABs relative to LABs (4-fold) is preserved invivo; the second modeled the difference in the HAB and MAB signalsin the context of an occupancy plot. Results: A 2-tissue-compartmentmodel described the data well, and a significant differencewas found between the VT of HABs, MABs, and LABs across allROIs examined (P , 0.05). We also found a significant correlationbetween VT and age for both HABs and MABs in most ROIs. Theaverage VND estimated by the 2 methods was 1.18 6 0.35 (methodI: VND 5 0.93, method II: VND 5 1.42), implying that the 18F-PBR111BPND was 2.78 6 0.46 in HABs, 1.48 6 0.28 in MABs, and 0.51 60.17 in LABs and that the in vivo affinity ratio was simil
Kandel ER, Markram H, Matthews PM, et al., 2013, VIEWPOINT Neuroscience thinks big (and collaboratively), NATURE REVIEWS NEUROSCIENCE, Vol: 14, Pages: 659-664, ISSN: 1471-003X
Matthews PM, Coatney R, Alsaid H, et al., 2013, Technologies: preclinical imaging for drug development., Drug Discov Today Technol, Vol: 10, Pages: e343-e350
Preclinical imaging with magnetic resonance imaging (MRI), computerised tomography (CT), ultrasound (US), positron emission tomography (PET) or single-photon emission computed tomography (SPECT) enable non-invasive measures of tissue structure, function or metabolism in vivo. The technologies can add value to preclinical studies by enabling dynamic pharmacological observations on the same animal and because of possibilities for relatively direct clinical translation. Potential benefits from the application of preclinical imaging should be considered routinely in drug development.
Newbould RD, Miller SR, Upadhyay N, et al., 2013, T1-Weighted Sodium MRI of the Articulator Cartilage in Osteoarthritis: A Cross Sectional and Longitudinal Study, PLOS One, Vol: 8, ISSN: 1932-6203
Khamis R, Woollard K, Chang SH, et al., 2013, The Near Infra-Red (NIRF) molecular imaging of oxidised LDL in atherosclerosis with the native autoantibody LO1, and its molecularly expressed cysteine-tagged Fab construct (LO1-Fab-cys), Congress of the European-Society-of-Cardiology (ESC), Publisher: OXFORD UNIV PRESS, Pages: 29-29, ISSN: 0195-668X
Petersen SE, Matthews PM, Bamberg F, et al., 2013, Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches, JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, Vol: 15, ISSN: 1097-6647
UK Biobank is a prospective cohort study with 500,000 participants aged 40 to 69. Recently an enhanced imagingstudy received funding. Cardiovascular magnetic resonance (CMR) will be part of a multi-organ, multi-modalityimaging visit in 3–4 dedicated UK Biobank imaging centres that will acquire and store imaging data from 100,000participants (subject to successful piloting). In each of UK Biobank’s dedicated bespoke imaging centres, it isproposed that 15–20 participants will undergo a 2 to 3 hour visit per day, seven days a week over a period of5–6 years. The imaging modalities will include brain MRI at 3 Tesla, CMR and abdominal MRI at 1.5 Tesla, carotidultrasound and DEXA scans using carefully selected protocols. We reviewed the rationale, challenges and proposedapproaches for concise phenotyping using CMR on such a large scale. Here, we discuss the benefits of this imagingstudy and review existing and planned population based cardiovascular imaging in prospective cohort studies. Wewill evaluate the CMR protocol, feasibility, process optimisation and costs. Procedures for incidental findings, qualitycontrol and data processing and analysis are also presented. As is the case for all other data in the UK Biobankresource, this database of images and related information will be made available through UK Biobank’s AccessProcedures to researchers (irrespective of their country of origin and whether they are academic or commercial)for health-related research that is in the public interest.
Khamis R, Woollard K, Granger D, et al., 2013, IMAGING BEYOND THE LUMEN: NEAR INFRA-RED IN VIVO MOLECULAR IDENTIFICATION OF OXIDISED LDL IN ATHEROSCLEROSIS USING MAB LO1, AND THE GENERATION AND DEVELOPMENT OF ITS MOLECULARLY EXPRESSED CYSTEINE-TAGGED CHIMERIC FAB CONSTRUCT (LO1-FAB-CYS), Annual Conference of the British-Cardiovascular-Society (BCS), Publisher: BMJ PUBLISHING GROUP, ISSN: 1355-6037
Ntusi NBA, Francis JM, Matthews PM, et al., 2013, SYSTEMIC LUPUS ERYTHEMATOSUS IS ASSOCIATED WITH IMPAIRED MYOCARDIAL STRAIN AND VASCULAR FUNCTION, INCREMENTAL TO THAT CAUSED BY TRADITIONAL RISK FACTORS: A CARDIOVASCULAR MAGNETIC RESONANCE STUDY, Annual Conference of the British-Cardiovascular-Society (BCS), Publisher: BMJ PUBLISHING GROUP, ISSN: 1355-6037
Ntusi NBA, Francis JM, Matthews PM, et al., 2013, MYOCARDIAL AND VASCULAR DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS ASSESSED WITH CARDIOVASCULAR MAGNETIC RESONANCE: EVIDENCE OF INCREASED VASCULAR RISK, Annual Conference of the British-Cardiovascular-Society (BCS), Publisher: BMJ PUBLISHING GROUP, Pages: A61-U238, ISSN: 1355-6037
Gourraud P-A, Sdika M, Khankhanian P, et al., 2013, A genome-wide association study of brain lesion distribution in multiple sclerosis, BRAIN, Vol: 136, Pages: 1012-1024, ISSN: 0006-8950
Matthews PM, Matthews EA, 2013, Expanding perception through the disordered brain., Lancet, Vol: 381, Pages: 985-986
Zarei M, Beckmann CF, Binnewijzend MAA, et al., 2013, Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease, NEUROIMAGE, Vol: 66, Pages: 28-35, ISSN: 1053-8119
Douaud G, Menke RAL, Gass A, et al., 2013, Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease, JOURNAL OF NEUROSCIENCE, Vol: 33, Pages: 2147-2155, ISSN: 0270-6474
Inkster B, Strijbis EMM, Vounou M, et al., 2013, Histone deacetylase gene variants predict brain volume changes in multiple sclerosis, NEUROBIOLOGY OF AGING, Vol: 34, Pages: 238-247, ISSN: 0197-4580
Matthews PM, Filippini N, Douaud G, 2013, Brain Structural and Functional Connectivity and the Progression of Neuropathology in Alzheimer's Disease, JOURNAL OF ALZHEIMERS DISEASE, Vol: 33, Pages: S163-S172, ISSN: 1387-2877
Owen D, Guo Q, Colasanti A, et al., 2013, Determination of [11C]PBR28 binding potential in vivo: A first human TSPO occupancy study., Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Libri V, Brown AP, Gambarota G, et al., 2012, A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers, PLoS ONE, Vol: 7, ISSN: 1932-6203
Background:SRT2104 has been developed as a selective small molecule activator of SIRT1, a NAD+-dependent deacetylaseinvolved in the regulation of energy homeostasis and the modulation of various metabolic pathways, including glucosemetabolism, oxidative stress and lipid metabolism. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. We report the first clinical trial of SRT2104 in elderlyvolunteers.Methods:Oral doses of 0.5 or 2.0 g SRT2104 or matching placebo were administered once daily for 28 days.Pharmacokinetic samples were collected through 24 hours post-dose on days 1 and 28. Multiple pharmacodynamicendpoints were explored with oral glucose tolerance tests (OGTT), serum lipid profiles, magnetic resonance imaging (MRI)for assessment of whole body visceral and subcutaneous fat, maximal aerobic capacity test and muscle 31P magneticresonance spectroscopy (MRS) for estimation of mitochondrial oxidative capacity.Results:SRT2104 was generally safe and well tolerated. Pharmacokinetic exposure increased less than dose-proportionally.Mean Tmax was 2–4 hours with elimination half-life of 15–20 hours. Serum cholesterol, LDL levels and triglyceridesdecreased with treatment. No significant changes in OGTT responses were observed. 31P MRS showed trends for morerapid calculated adenosine diphosphate (ADP) and phosphocreatine (PCr) recoveries after exercise, consistent withincreased mitochondrial oxidative phosphorylation.Conclusions:SRT2104 can be safely administered in elderly individuals and has biological effects in humans that areconsistent with SIRT1 activation. The results of this study support further development of SRT2104 and may be useful indose selection for future clinical trials in patients.
Matthews PM, Filippini N, Douaud G, 2012, Brain structural and functional connectivity and the progression of neuropathology in Alzheimer's disease, ISBN: 9781614991533
In our contribution to this special issue focusing on advances in Alzheimer's disease (AD) research since the centennial, we will briefly review some of our own studies applying magnetic resonance imaging (MRI) measures of function and connectivity for characterization of genetic contributions to the neuropathology of AD and as candidate biomarkers. We review how functional MRI during both memory encoding and at rest is able to define APOE4 genotype-dependent physiological changes decades before potential development of AD and demonstrate changes distinct from those with healthy aging. More generally, imaging provides a powerful quantitative measure of phenotype for understanding associations arising from whole genome studies in AD. Structural connectivity measures derived from diffusion tensor MRI (DTI) methods offer additional markers of neuropathology arising from the secondary changes in axonal caliber and myelination that accompany decreased neuronal activity and neurodegeneration. We illustrate applications of DTI for more finely mapping neurodegenerative changes with AD in the thalamus in vivo and for defining neuropathological changes in the white matter itself. The latter efforts have highlighted how sensitivity to the neuropathology can be enhanced by using more specific DTI measures and interpreting them relative to knowledge of local white matter anatomy in the healthy brain. Together, our studies and related work are helping to establish the exciting potential of a new range of MRI methods as neuropathological measures and as biomarkers of disease progression. © 2013 The authors and IOS Press. All rights reserved.
Gelineau-Morel R, Tomassini V, Jenkinson M, et al., 2012, The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis, HUMAN BRAIN MAPPING, Vol: 33, Pages: 2802-2814, ISSN: 1065-9471
Tomassini V, Matthews PM, Thompson AJ, et al., 2012, Neuroplasticity and functional recovery in multiple sclerosis, NATURE REVIEWS NEUROLOGY, Vol: 8, Pages: 635-646, ISSN: 1759-4758
Fleming IN, Whelan M, Baxendale R, et al., 2012, Positron emission tomography radiopharmaceutical studies in humans: a guide to regulations for academic researchers, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 33, Pages: 899-906, ISSN: 0143-3636
Allen N, Sudlow C, Downey P, et al., 2012, UK Biobank: Current status and what it means for epidemiology, HEALTH POLICY AND TECHNOLOGY, Vol: 1, Pages: 123-126, ISSN: 2211-8837
Matthews PM, 2012, Clinical imaging in drug development, Drug Discovery and Development: Technology in Transition, Pages: 259-274, ISBN: 9780702042997
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.